Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis

OBJECTIVE: To assess the frequency of cardiovascular and venous thromboembolic events in clinical studies of baricitinib, an oral, selective JAK1 and JAK2 inhibitor approved in more than 50 countries for the treatment of moderately‐to‐severely active rheumatoid arthritis (RA). METHODS: Data were poo...

Descripción completa

Detalles Bibliográficos
Autores principales: Taylor, Peter C., Weinblatt, Michael E., Burmester, Gerd R., Rooney, Terence P., Witt, Sarah, Walls, Chad D., Issa, Maher, Salinas, Claudia A., Saifan, Chadi, Zhang, Xin, Cardoso, Anabela, González‐Gay, Miguel A., Takeuchi, Tsutomu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6618316/
https://www.ncbi.nlm.nih.gov/pubmed/30663869
http://dx.doi.org/10.1002/art.40841

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6618316/
https://www.ncbi.nlm.nih.gov/pubmed/30663869
http://dx.doi.org/10.1002/art.40841

Ejemplares similares